We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bristol-Myers Squibb shareholders panicked on Wednesday when its largest institutional shareholder, Wellington Management, came out against its $74 billion acquisition of Celgene—and activist hedge fund Starboard Value immediately followed suit.